Exact Sciences Corporation EXAS
Mar 23, 2026, 9:30 AM EDT
52-week range unavailable
- YTD
- +3.30%
- 1 year
- +129.96%
- Market cap
- 20.03B
- Profit margin
- -4.20%
- YTD return
- +3.30%
- 1-year return
- +129.96%
- Volume
- 21.56M
- Open
- 104.91
- Previous close
- 104.91
- Day's range
- 104.91 – 104.91
Key statistics
- Enterprise value
- 21.59B
- PEG ratio
- -2.15
- Price / sales
- 0.00
- Price / book
- 8.29
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 13
- Return on equity
- -4.34%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy1
- Buy0
- Hold11
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 13, 2026 | Dec 31, 2025 | -0.10793 | -0.45 | -0.34 | -316.94% |
| Nov 3, 2025 | Sep 30, 2025 | -0.06122 | 0.24 | +0.30 | +492.03% |
| Aug 6, 2025 | Jun 30, 2025 | -0.02 | 0.22 | +0.24 | +1,200.00% |
| May 1, 2025 | Mar 31, 2025 | -0.37 | -0.54 | -0.17 | -45.95% |
| Feb 19, 2025 | Dec 31, 2024 | -0.29 | -0.06 | +0.23 | +79.31% |
| Nov 5, 2024 | Sep 30, 2024 | -0.19589 | -0.21 | -0.01 | -7.20% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 20, 2026 | Mizuho | down | Outperform | Neutral |
| Jan 5, 2026 | Evercore ISI Group | down | Outperform | In-Line |
| Nov 28, 2025 | Stifel | down | Buy | Hold |
| Nov 25, 2025 | Canaccord Genuity | down | Buy | Hold |
| Nov 24, 2025 | Benchmark | down | Buy | Hold |
| Nov 24, 2025 | Jefferies | down | Buy | Hold |
About Exact Sciences Corporation
Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- US
- Employees
- 6,900
- Website
- exactsciences.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on EXAS — it syncs with the Stock Master app.